149965-92-4

Usage

Uses

Used in Anticancer Applications:
5-Fluorouridine-5'-O-b-D-galactopyranoside is used as a prodrug in the treatment of various types of cancer. It is particularly effective against solid tumors, as it can be converted into the active form by the action of β-d-galactosidase, an enzyme that is often overexpressed in cancer cells. This selective activation allows for targeted therapy with reduced side effects on healthy cells.
Used in Drug Delivery Systems:
In the pharmaceutical industry, 5-Fluorouridine-5'-O-b-D-galactopyranoside is used as a component in drug delivery systems designed to improve the specificity and efficacy of cancer treatments. These systems can include encapsulation within nanoparticles or conjugation to monoclonal antibodies, such as COL-1, to enhance the selective delivery of the prodrug to cancer cells and increase the overall therapeutic effect.
Used in Research and Development:
5-Fluorouridine-5'-O-b-D-galactopyranoside is also utilized in the field of biomedical research as a tool to study the mechanisms of cancer cell death and to develop new strategies for cancer treatment. Its unique activation pathway and the ability to be selectively converted by certain enzymes make it an interesting compound for investigating the role of these enzymes in cancer progression and for designing targeted therapies.

Relevant academic research and scientific papers

Synthesis of disaccharide nucleosides utilizing the temporary protection of the 20,30-cis-diol of ribonucleosides by a boronic ester

Disaccharide nucleosides are an important class of natural compounds that have a variety of biological activities. In this study, we report on the synthesis of disaccharide nucleosides utilizing the temporary protection of the 20,30-cis-diol of ribonucleosides, such as adenosine, guanosine, uridine, 5-metyluridine, 5-fluorouridine and cytidine, by a boronic ester. The temporary protection of the above ribonucleosides permits the regioselective O-glycosylation of the 5'-hydroxyl group with thioglycosides using a p-toluenesulfenyl chloride (p-TolSCl)/silver triflate (AgOTf) promoter system to afford the corresponding disaccharide nucleosides in fairly good chemical yields. The formation of a boronic ester prepared from uridine and 4-(trifluoromethyl)phenylboronic acid was examined by 1H, 11B and 19F NMR spectroscopy.

Compositions and methods for targeted enzymatic release of cell regulatory compounds

Novel pro-drugs and methods for their use to alter the growth and biological characteristics of living cells, tissues, or whole organisms are described. The methods allow for selective activation of the pro-drugs at or near transformant host cells expressing a gene for an enzyme that activates the pro-drugs. Pro-drugs according to a preferred embodiment of the invention are conjugates of a bioactive compound and a chemical group that is capable of being cleaved from the bioactive compound by action of an enzyme. Methods according to this invention include, (a) introducing into targeted cells a gene encoding an enzyme and (b) administering a pro-drug, wherein the enzyme releases the pro-drug from conjugation. In a preferred embodiment of the invention, the gene encoding the enzyme is a marker gene.